Treatment of ADHD in adults – prevalence of discontinuation and associated factors – results from a cross-sectional analysis of Danish register data

References

• Caye A, Swanson J, Thapar A, et al. Life Span Studies of ADHD—conceptual challenges and predictors of persistence and outcome. Curr Psychiatry Rep. 2016;18(12):111.
   PubMed Web of Science ®Google Scholar
• Chang Z, D’Onofrio BM, Quinn PD, et al. Medication for attention-deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study. Biol Psychiatry. 2016;80(12):916–922.
   PubMed Web of Science ®Google Scholar
• Simon V, Czobor P, Bálint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194(3):204–211.
   PubMed Web of Science ®Google Scholar
• Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738.
   PubMed Web of Science ®Google Scholar
• Cunill R, Castells X, Tobias A, et al. Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients. Psychopharmacology. 2016;233(2):187–197.
   PubMed Web of Science ®Google Scholar
• NICE. 2018. Attention deficit hyperactivity disorder: diagnosis and management [NG87]. [cited 2018 Dec 11]. Available from https://www.nice.org.uk/guidance/ng87
   Google Scholar
• Chang Z, Lichtenstein P, D’Onofrio BM, et al. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication. JAMA Psychiatry. 2014;71(3):319–325.
   PubMed Web of Science ®Google Scholar
• Chang Z, Quinn PD, Hur K, et al. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry. 2017;74(6):597–603.
   PubMed Web of Science ®Google Scholar
• Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit–hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006–2014.
   PubMed Web of Science ®Google Scholar
• Caye A, Swanson JM, Coghill D, et al. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry. 2019;24(3):390–408.
   PubMed Web of Science ®Google Scholar
• Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543–1569.
   PubMed Web of Science ®Google Scholar
• Bahmanyar S, Sundström A, Kaijser M, et al. Pharmacological treatment and demographic characteristics of pediatric patients with Attention Deficit Hyperactivity Disorder, Sweden. Eur Neuropsychopharmacol. 2013;23(12):1732–1738.
   PubMed Web of Science ®Google Scholar
• Pottegård A, Bjerregaard BK, Kortegaard LS, et al. Early discontinuation of attention-deficit/hyperactivity disorder drug treatment: a Danish Nationwide Drug Utilization Study. Basic Clin Pharmacol Toxicol. 2015;116(4):349–353.
   PubMed Web of Science ®Google Scholar
• Bhang S-Y, Hwang J-W, Kwak Y-S, et al. Differences in utilization patterns among medications in children and adolescents with attention-deficit/hyperactivity disorder: a 36-month retrospective study using the Korean Health Insurance Review and Assessment Claims Database. J Korean Med Sci. 2016;31(8):1284–1291.
   PubMed Web of Science ®Google Scholar
• Ferrin M, Taylor E. Child and caregiver issues in the treatment of attention deficit hyperactivity disorder: education, adherence and treatment choice. Future Neurol. 2011;6(3):399–413.
   Google Scholar
• Newlove-Delgado T, Ford TJ, Hamilton W, et al. Prescribing of medication for attention deficit hyperactivity disorder among young people in the Clinical Practice Research Datalink 2005–2013: analysis of time to cessation. Eur Child Adolesc Psychiatry. 2018;27(1):29–35.
   PubMed Web of Science ®Google Scholar
• Pottegård A, Bjerregaard BK, Glintborg D, et al. The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective. Eur J Clin Pharmacol. 2013;69(3):589–598.
   PubMed Web of Science ®Google Scholar
• Wang L-J, Yang K-C, Lee S-Y, et al. Initiation and persistence of pharmacotherapy for youths with attention deficit hyperactivity disorder in Taiwan. PLoS One. 2016;11(8):e0161061.
   PubMed Web of Science ®Google Scholar
• Wu SH, Wang K, Chen Y, et al. Exploratory analysis of early treatment discontinuation and clinical outcomes of patients with attention-deficit/hyperactivity disorder. Asia-Pac Psychiatry : Off J Pac Rim Coll Psychiatrists. 2017;9(1):e12231.
   Web of Science ®Google Scholar
• Zetterqvist J, Asherson P, Halldner L, et al. Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006–2009. Acta Psychiatr Scand. 2013;128(1):70–77.
   PubMed Web of Science ®Google Scholar
• Brinkman WB, Sherman SN, Zmitrovich AR, et al. In their own words: adolescent views on ADHD and their evolving role managing medication. Acad Pediatr. 2012;12(1):53–61.
   PubMed Web of Science ®Google Scholar
• Kooij JJS, Rösler M, Philipsen A, et al. Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial. BMC Psychiatry. 2013;13(1):36.
   PubMedGoogle Scholar
• Soendergaard HM, Thomsen PH, Pedersen P, et al. Treatment dropout and missed appointments among adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2016;77(02):232–239.
   PubMedGoogle Scholar
• Matheson L, Asherson P, Wong ICK, et al. Adult ADHD patient experiences of impairment, service provision and clinical management in England: a qualitative study. BMC Health Serv Res. 2013;13(1):184.
   PubMedGoogle Scholar
• Erlangsen A, Fedyszyn I. Danish nationwide registers for public health and health-related research. Scand J Public Health. 2015;43(4):333–339.
   PubMed Web of Science ®Google Scholar
• IBM Corp. Released. 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk (NY): IBM Corp.
   Google Scholar
• Thorell LB, Holst Y, Sjöwall D. Quality of life in older adults with ADHD: links to ADHD symptom levels and executive functioning deficits. Nordic J Psychiatry. 2019;73(7):409–416.
   PubMed Web of Science ®Google Scholar
• Jangmo A, Stalhandske A, Chang Z, et al. Attention-deficit/hyperactivity disorder, school performance, and effect of medication. J Am Acad Child Adolesc Psychiatry. 2019;58(4):423–432.
   PubMed Web of Science ®Google Scholar
• Keilow M, Holm A, Fallesen P. Medical treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and children’s academic performance. PLoS One. 2018;13(11):e0207905.
   PubMed Web of Science ®Google Scholar
• Mohr-Jensen C, Müller-Bisgaard C, Boldsen SK, et al. Attention-Deficit/Hyperactivity Disorder in Childhood and Adolescence and the risk of crime in young adulthood in a Danish Nationwide Study. J Am Acad Child Adolesc Psyhiatry. 2019;58(4):443–452.
   PubMed Web of Science ®Google Scholar
• Jensen CM, Steinhausen H-C. Time trends in incidence rates of diagnosed attention-deficit/hyperactivity disorder across 16 years in a Nationwide Danish Registry Study. J Clin Psychiatry. 2015;76(03):e334–e341.
   PubMedGoogle Scholar
• Bang Madsen K. 2017. The pathway to an ADHD diagnosis Exploring the influence of factors at the structural, community, family and child level. Aarhus University.
   Google Scholar
• Emilsson M, Gustafsson PA, Öhnström G, et al. Beliefs regarding medication and side effects influence treatment adherence in adolescents with attention deficit hyperactivity disorder. Eur Child Adolesc Psychiatry. 2017;26(5):559–571.
   PubMed Web of Science ®Google Scholar
• Kosse RC, Bouvy ML, Philbert D, et al. Attention-Deficit/Hyperactivity Disorder medication use in adolescents: the patient’s perspective. J Adolesc Health. 2017;61(5):619–625.
   PubMed Web of Science ®Google Scholar
• Newlove-Delgado T, Ford TJ, Hamilton W, et al. Resumption of attention-deficit hyperactivity disorder medication in early adulthood: findings from a UK primary care prescribing study. Eur Child Adolesc Psychiatry. 2019;28:1–8. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Nylander L, Holmqvist M, Gustafson L, et al. Attention-Deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) in adult psychiatry. A 20-year register study. Nordic J Psychiatry. 2013;67(5):344–350.
   PubMed Web of Science ®Google Scholar
• Semerci B, Taskıran S, Tufan E, et al. Factors predicting treatment adherence in patients with adult attention-deficit/hyperactivity disorder: a preliminary study. ADHD Atten Def Hyp Disord. 2016;8(3):139–147.
   PubMedGoogle Scholar
• Sobanski E, Retz W, Fischer R, et al. Treatment adherence and persistence in adult ADHD: results from a twenty-four week controlled clinical trial with extended release methylphenidate. Eur Psychiatry. 2014;29(5):324–330.
   PubMed Web of Science ®Google Scholar